NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 03/11/2026 at 13:35, 5 days 4 hours ago

NanoViricides to Present at NIBA Conference and Announces Completion of NV-387 Production

NanoViricides NV-387 Antiviral Drugs Phase II Trials NIBA Conference
PRESS RELEASE

published on 03/11/2026 at 13:30, 5 days 4 hours ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
NanoViricides, Inc. announces completion of manufacture for NV-387 Oral Gummies clinical trial. President to present at NIBA conference. Lead drug NV-387 to target various viral infections

NanoViricides NV-387 Clinical Trial Antiviral NIBA Conference
BRIEF

published on 02/12/2026 at 14:35, 1 month 4 days ago

NanoViricides Files Orphan Drug Application for NV-387 as MPox Treatment

NanoViricides NV-387 Orphan Drug Designation FDA Application MPOX Treatment
PRESS RELEASE

published on 02/12/2026 at 14:30, 1 month 4 days ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
NanoViricides files Orphan Drug Designation application with US FDA for NV-387 as treatment for MPox, a contagious disease with potential global pandemic threat

NanoViricides NV-387 Orphan Drug Designation Mpox US FDA
BRIEF

published on 02/10/2026 at 14:35, 1 month 6 days ago

NanoViricides Pursues Orphan Drug Designation for Measles Treatment

NanoViricides NV-387 FDA Approval Orphan Drug Designation Measles Treatment
PRESS RELEASE

published on 02/10/2026 at 14:30, 1 month 6 days ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
NanoViricides files for Orphan Drug Designation for NV-387 as Measles treatment with potential FDA incentives. Strong in vivo activity against Measles shown in humanized animal model study

NanoViricides NV-387 Orphan Drug Designation Measles Treatment FDA Incentives
BRIEF

published on 02/02/2026 at 14:35, 1 month 14 days ago

NanoViricides Showcases Antiviral Advancements with NV-387

NanoViricides NV-387 Clinical Trials Antiviral Therapy Broad-spectrum
PRESS RELEASE

published on 02/02/2026 at 14:30, 1 month 14 days ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
NanoViricides, Inc. announces President Dr. Anil R. Diwan's interview on Mission Matters Podcast discussing revolutionary antiviral drugs development and NV-387 efficacy against various viruses

NV-387 Antiviral Drugs NanoViricides Inc. Dr. Anil R. Diwan Mission Matters Podcast
BRIEF

published on 01/13/2026 at 14:35, 2 months 3 days ago

NanoViricides Highlights Need for Broad-Spectrum Antivirals Amid Influenza Surge

NV-387 Respiratory Infections Broad-spectrum Antivirals Influenza Virus Antiviral Resistance
PRESS RELEASE

published on 01/13/2026 at 14:30, 2 months 3 days ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides, Inc. declares need for broad-spectrum antivirals amid severe influenza epidemic, highlighting potential of NV-387 against multiple viruses

NanoViricides NV-387 Respiratory Viruses Broad-spectrum Antivirals Influenza Epidemic

Published on 03/16/2026 at 14:00, 4 hours 10 minutes ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Published on 03/16/2026 at 13:45, 4 hours 25 minutes ago

iFabric Corp Provides Strong 2025 Revenue Estimate and 2026 Outlook
Published on 03/16/2026 at 13:30, 4 hours 40 minutes ago

Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense
Published on 03/16/2026 at 13:30, 4 hours 40 minutes ago

An Asteroid Just Hit Earth - Where Did Everything Land? New Global Challenge Seeks Answers
Published on 03/16/2026 at 13:30, 4 hours 40 minutes ago

Tactical Resources Signs Agreement to Acquire the Sierra Blanca Quarry and Tailings Access for the Peak Rare Earth Project

View all ACCESSWIRE

Published on 03/16/2026 at 17:47, 23 minutes ago

Key Figures 15.03.2026
Published on 03/16/2026 at 17:15, 55 minutes ago

EU Council Removes Niels Troost from Russia Sanctions List
Published on 03/16/2026 at 15:47, 2 hours 22 minutes ago

EQS-Adhoc: CEWE Stiftung & Co. KGaA: CEWE plans 17th dividend increase in a row
Published on 03/16/2026 at 15:45, 2 hours 25 minutes ago

TR-1: notification of major holdings
Published on 03/16/2026 at 14:25, 3 hours 45 minutes ago

Holding(s) in Company

View all EQS

Published on 03/16/2026 at 18:00, 10 minutes ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 12 minutes ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 13 minutes ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 25 minutes ago

Weekly share buyback
Published on 03/16/2026 at 17:35, 35 minutes ago

Disclosure of transactions in own shares from March 9 to March 13, 2026

View all LES ECHOS COMFI WIRE

News